Imfinzi Plus Chemotherapy Approved in the US for Mismatch Repair Deficient Advanced or Recurrent Endometrial Cancer
June 18, 2024
June 18, 2024
WILMINGTON, Delaware, June 18 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
AstraZeneca's followed by IMFINZI monotherapy has been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).1
The approval by the Food and Drug Administration (FDA) was based on the results of a prespecified exploratory subgroup analysis by MMR status in the DUO . . .
AstraZeneca's followed by IMFINZI monotherapy has been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).1
The approval by the Food and Drug Administration (FDA) was based on the results of a prespecified exploratory subgroup analysis by MMR status in the DUO . . .